Spruce Biosciences Inc (NAS:SPRB)
$ 0.4356 0.0106 (2.49%) Market Cap: 17.99 Mil Enterprise Value: -48.44 Mil PE Ratio: 0 PB Ratio: 0.30 GF Score: 35/100

Spruce Biosciences Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 01:30PM GMT
Release Date Price: $2.31 (-0.86%)
Unidentified Participant

Javier Szwarcberg, CEO of Bruce Biosciences.

Javier Szwarcberg
Spruce Biosciences, Inc. - CEO

Thank you, Russell, and thank you, Jefferies, for having me and Spruce here. A real pleasure to be sharing our company and our data.

So, I guess I have a clicker. So, I'll be making some forward-looking statements along my presentation. I'll refer you to prior SEC filings and prior press releases and other sources of communications that we've issued in the past.

So let me tell you a little bit about Spruce. So, we're a rare disease endocrinology company. We're developing tildacerfont for the treatment of CAH and PCOS. And pretty excited to be moving our programs forward. We believe the CAH market is a fairly large commercial opportunity of approximately $3 billion. There is significant unmet need. There has been no innovation in the CAH field for over 50, 60 years, mainly since the advent of synthetic steroids.

We in-licensed tildacerfont from Eli Lilly in 2016. tildacerfont is a second-generation CRF-1 receptor antagonist.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot